FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Practices, Cut Patient Costs

The FTC has settled with CVS Caremark over insulin rebate practices that inflated patient costs, requiring the pharmacy benefit manager to pass through more rebates to patients and reduce spread pricing on insulin. This settlement directly targets the middleman markup that has driven insulin affordability crises.

This Wire brief sits within Fusion42's coverage of Digital Health.